#AbeoIt is amazing chart with invesetor or speculator
5.00$ it is good point to build Buying centers with stop loss under 3.50 $ for short term
First target for speculator 8.00 to8.70$
First Target for invesetor 21$ then 49$
−2.60USD
−54.19 MUSD
3.50 MUSD
25.91 M
About ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT)
Sector
CEO
Vishwas Seshadri
Headquarters
Cleveland
Website
Employees (FY)
84
Founded
1974
ISIN
US00289Y2063
FIGI
BBG00JVRN1C3
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from T
50/50 triangle, but still below the 200 (bearish)looks like a picture-perfect triangle. Wait for confirmation and good luck.
ABEO LongAbeona Therapeutics Inc is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases. I guess the stock can surge at least to $4.94.
My trade levels:
Entry: $3.92
Take profit: $4.94
Stop loss: $3.59
Risk/reward: 3.09
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action h
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated
ABEOLooking at the gap around $1.10 for a possible position.
For my educational purpose, not to be used as financial advice.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0H7R is 8.40 USD — it has increased by 7.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stocks are traded under the ticker 0H7R.
ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) has a max estimate of 36.00 USD and a min estimate of 12.00 USD.
0H7R earnings for the last quarter are −0.48 USD whereas the estimation was −0.53 USD which accounts for 10.00% surprise. Estimated earnings for the next quarter are −0.47 USD. See more details about ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) earnings.
ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 1.00 M USD.
Yes, you can track ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
Like other stocks, 0H7R shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 84.00 employees. See our rating of the largest employees — is ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) EBITDA is −45.00 M USD, and current EBITDA margin is −1.29 K%. See more stats in ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) financial statements.